Validation and qualification of a multiplex hypoxia biomarker for radiotherapy individualisation

用于放射治疗个体化的多重缺氧生物标志物的验证和鉴定

• 批准号: G0801525/1
• 负责人: Catharine West
• 金额: $ 89.6万
• 依托单位: University of Manchester
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2009
• 资助国家: 英国
• 起止时间: 2009 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0801525%2F1
• 关键词: Validation; qualification; multiplex; hypoxia; biomarker

What is the background of this research?Approximately 300,000 patients develop cancer in the UK each year, and around 50% will undergo radiotherapy at some point during treatment. Hypoxia (meaning ?low oxygen?) in a tumour is associated with resistance to radiotherapy. If doctors could identify whether a tumour was hypoxic, it would help them improve treatment to give the best chance of cure for a patient.What is the research trying to achieve?Previous research identified a group of 99 genes that are linked with hypoxia in head and neck tumours. More recently this group has been refined to a subset that comprises just 30 genes. This research aims to confirm whether the reduced 30-gene group can be used in the clinic as a test for hypoxia. To do this, we will be using tumour samples collected from patients who chose to take part in a clinical trial. We know there is a special pattern of activity in these 30 genes that reflects oxygen levels in a tumour. We are investigating different ways of identifying this pattern to find the one which is most reliable and reproducible, and therefore most useful in the clinic.We also want to investigate whether our pattern of 30 genes can identify and predict hypoxia in other cancers e.g. bladder. We will investigate whether a different 30-gene group is needed for each cancer type.Why is this important?If we are able to develop a reliable test for hypoxia, we could try it out in a clinical trial. If successful it could be introduced into clinical practice. This would mean patients would receive the treatment that is best for them, which would improve outcome. Given the large number of cancer patients who undergo radiotherapy each year, this would have a significant benefit on cancer survival in the UK.How and where is the research to be conducted?This study builds on long-standing collaborations between scientists and doctors from across the UK and EU. It will be led by Dr. Catharine West at the University of Manchester, who has many years experience of measuring tumour hypoxia in patients. This study will use tumour samples collected from patients who gave full and informed consent for their tissue to be used in future ethically approved research.

本研究的背景是什么？在英国，每年约有30万名患者患上癌症，其中约50%的患者在治疗期间的某个时候会接受放射治疗。Hypoxia（缺氧）是什么意思？低氧？）与对放射治疗的抵抗力有关。如果医生能够识别肿瘤是否缺氧，这将有助于他们改善治疗，为患者提供最佳的治愈机会。这项研究试图实现什么？先前的研究确定了一组与头颈部肿瘤缺氧有关的99个基因。最近，这一组基因已经被细化为仅包含30个基因的子集。这项研究旨在确认减少的30个基因组是否可以在临床上用作缺氧测试。为此，我们将使用从选择参加临床试验的患者中收集的肿瘤样本。我们知道这30个基因中有一种特殊的活性模式，反映了肿瘤中的氧气水平。我们正在研究识别这种模式的不同方法，以找到最可靠和可重复的方法，因此在临床上最有用。我们还想研究我们的30个基因模式是否可以识别和预测其他癌症（如膀胱癌）中的缺氧。我们将研究每种癌症类型是否需要不同的30个基因组。为什么这很重要？如果我们能够开发出一种可靠的缺氧测试方法，我们就可以在临床试验中试用。如果成功的话，它可以被引入临床实践。这将意味着患者将接受最适合他们的治疗，这将改善结果。鉴于每年接受放射治疗的癌症患者数量庞大，这将对英国癌症患者的生存率产生重大影响。如何以及在哪里进行研究？这项研究建立在来自英国和欧盟的科学家和医生之间的长期合作基础上。它将由曼彻斯特大学的Catharine West博士领导，他在测量患者肿瘤缺氧方面有多年的经验。本研究将使用从患者中收集的肿瘤样本，这些患者完全知情同意将其组织用于未来伦理批准的研究。